tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2020 Jun 5;7(7)
faa219.
doi: 10.1093/ofid/ofaa219. eCollection 2020 Jul.
Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence
Daniel B Chastain[SUP] 1 [/SUP], Tia M Stitt[SUP] 1 2 [/SUP], Phong T Ly[SUP] 1 2 [/SUP], Andr?s F Henao-Mart?nez[SUP] 3 [/SUP], Carlos Franco-Paredes[SUP] 3 4 [/SUP], Sharmon P Osae[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 is associated with higher concentrations of proinflammatory cytokines that lead to lung damage, respiratory failure, and resultant increased mortality. Immunomodulatory therapy has the potential to inhibit cytokines and quell the immune dysregulation. Controversial data found improved oxygenation after treatment with tocilizumab, an interleukin-6 inhibitor, sparking a wave of interest and resultant clinical trials evaluating immunomodulatory therapies. The purpose of this article is to assess potential proinflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with coronavirus disease 2019.
Keywords: ARDS; COVID-19; SARS-CoV-2; cytokine storm; tocilizumab.
. 2020 Jun 5;7(7)
faa219.doi: 10.1093/ofid/ofaa219. eCollection 2020 Jul.
Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence
Daniel B Chastain[SUP] 1 [/SUP], Tia M Stitt[SUP] 1 2 [/SUP], Phong T Ly[SUP] 1 2 [/SUP], Andr?s F Henao-Mart?nez[SUP] 3 [/SUP], Carlos Franco-Paredes[SUP] 3 4 [/SUP], Sharmon P Osae[SUP] 1 [/SUP]
Affiliations
- PMID: 32691007
- PMCID: PMC7313774
- DOI: 10.1093/ofid/ofaa219
Abstract
Severe acute respiratory syndrome coronavirus 2 is associated with higher concentrations of proinflammatory cytokines that lead to lung damage, respiratory failure, and resultant increased mortality. Immunomodulatory therapy has the potential to inhibit cytokines and quell the immune dysregulation. Controversial data found improved oxygenation after treatment with tocilizumab, an interleukin-6 inhibitor, sparking a wave of interest and resultant clinical trials evaluating immunomodulatory therapies. The purpose of this article is to assess potential proinflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with coronavirus disease 2019.
Keywords: ARDS; COVID-19; SARS-CoV-2; cytokine storm; tocilizumab.